Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 30, 2016 08:30 ET | Source: Mateon Therapeutics

Oxigene Receives Fast Track Designation From U.S. FDA for CA4P

SOUTH SAN FRANCISCO, Calif., March 30, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer,...
March 28, 2016 08:30 ET | Source: Mateon Therapeutics

OXiGENE Reports 2015 Financial Results

SOUTH SAN FRANCISCO, Calif., March 28, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer,...
March 25, 2016 08:30 ET | Source: Mateon Therapeutics

OXiGENE Receives European Orphan Drug Designation for CA4P to Treat Neuroendocrine Tumors

SOUTH SAN FRANCISCO, Calif., March 25, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer,...
March 24, 2016 08:30 ET | Source: Mateon Therapeutics

OXiGENE Appoints Dr. Simon Pedder to Board of Directors

SOUTH SAN FRANCISCO, Calif., March 24, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer,...
February 03, 2016 09:00 ET | Source: Mateon Therapeutics

OXiGENE Announces Upcoming Presentation at the BIO-CEO Conference and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment...
January 06, 2016 08:00 ET | Source: Mateon Therapeutics

OXiGENE Receives U.S. Orphan Drug Designation for CA4P to Treat Neuroendocrine Tumors

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer,...
December 17, 2015 15:00 ET | Source: Mateon Therapeutics

OXiGENE Receives European Orphan Drug Designation for OXi4503 to Treat Acute Myeloid Leukemia

SOUTH SAN FRANCISCO, Calif., Dec. 17, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer,...
November 10, 2015 16:15 ET | Source: Mateon Therapeutics

OXiGENE Reports Third Quarter 2015 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today...
November 05, 2015 16:15 ET | Source: Mateon Therapeutics

OXiGENE Announces Positive Initial Data From Phase 1b Study of CA4P in Combination With Pazopanib in Patients With Advanced Recurrent Ovarian Cancer

SOUTH SAN FRANCISCO, Calif., Nov. 5, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today...
October 21, 2015 16:15 ET | Source: Mateon Therapeutics

OXiGENE Announces Initiation of Phase 1b/2 Clinical Trial of OXi4503 in Acute Myeloid Leukemia

First patient dosed in OXiGENE-sponsored expansion of investigator trial Phase 1b/2 dose-escalation study of OXi4503 as a single agent and in combination with cytarabine SOUTH SAN...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right